Get started

Bounce

Bullish On AKRX - Possible Bounce HighAkorn, Inc. engages in the development, manufacture, and marketing of generic and prescription pharmaceuticals, and animal and consumer health products. It operates through the Prescription Pharmaceuticals and Consumer Health business segments. The Prescription Pharmaceuticals segment manufactures and markets generic and branded prescription pharmaceuticals including ophthalmic, injectable, oral liquids, topical, inhalants, and nasal sprays. The Consumer Health segment offers branded and private-label animal health; and over-the-counter products. The company was founded in 1971 and is headquartered in Lake Forest, IL. SHORT INTEREST 13.42M 08/15/19 P/E Current -0.84 P/E Ratio (with extraordinary items) -0.71 Average Recommendation: OVERWEIGHT Average Target Price: 6.30
ALong
by DEXWireNews
PRTK - On Track For Bounce UpParatek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA. SHORT INTEREST 10.98M 08/15/19 P/E Current -1.05 P/E Ratio (with extraordinary items) -0.98 Average Recommendation: BUY Average Target Price: 21.33
PLong
by DEXWireNews
I will hold my shorts until TPs/SLs hit, or confirmations..Well, there are many indicators that show that we are going to bounce.. - sma200 ema200 on 4h - fear index extreemly low - some other indicators show that we are at the lowest point such as rsi.. - also we didnt have pull back yet (to prepare for next drop if there is going to be any?) - we sliced the cloud downwards on hourly, but now need to test it out again (pull back) *** and more... but all these indicators aren't a must, especially if we are going to see long red weekly dildos, sure small consolidation/pullBack is nice to have, but dont forget that there are also a lot of indicators showing that we can continue going down.. This is why for those who shorted with me, I told to take some profits (15% at-list), and to move SLs to a profit area.. but Im not done shorting, Im still in both positions, and I still believe we are going to meet at-list 2 of my TPs: 10300, 9450, 8450- (from my perspective these are much more probable then going back to 11k+ atm.... but as I said that everything is just probabilities, we cant always catch the edges, and we cant always catch the right direction, thus all who did short so far I would recomand to keep at profit levels and hold positions until either TPs/SL hit or until we have confirmation for drastic market change, those who aren't in position should wait for a better position (I think a closing candle today or weekly should tell direction) - never rush a trade because this is how you lose money.. those who want to try to long this falling knife are welcome but dont risk too much, keep it safe trading.
BITMEX:BTCUSD.PShort
by Hedgehog_king
GMDA - Slight Bullish Divergence. Could Recover Market LossesGamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure blood cancer and rare serious hematologic diseases. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel. SHORT INTEREST 30.41K 07/31/19 P/E Current -0.33 P/E Ratio (with extraordinary items) -1.65 Average Recommendation: BUY Average Target Price: 18.00
GLong
by DEXWireNews
MCRB - Bounce Trend In Flow - Can It Carry On?Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA. SHORT INTEREST 4.91M 07/31/19 P/E Current -1.22 P/E Ratio (with extraordinary items) -1.71 Average Recommendation: OVERWEIGHT Average Target Price: 9.60
NASDAQ:MCRB
by DEXWireNews